SPX3,655.04-38.19 -1.03%
DIA292.72-3.14 -1.06%
IXIC10,802.92-65.00 -0.60%

Berenberg Initiates Coverage On POINT Biopharma Global with Buy Rating, Announces Price Target of $20

Berenberg analyst Zhiqiang Shu initiates coverage on POINT Biopharma Global (NASDAQ:PNT) with a Buy rating and announces Price Target of $20.

Benzinga · 09/14/2022 06:44
Berenberg analyst Zhiqiang Shu initiates coverage on POINT Biopharma Global (NASDAQ:PNT) with a Buy rating and announces Price Target of $20.